Damora Therapeutics, Inc. (GLTO) Stock Analysis & Investment Frameworks
Damora Therapeutics, Inc. (GLTO) stock analysis on Invetso. Review Damora Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Damora Therapeutics, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: US
Damora Therapeutics, Inc. Key Financial Metrics
- Market Cap: $34.47M
- Revenue: $N/A
- ROE: -66.20%
- ROIC: -61.25%
- Dividend Yield: N/A
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.